Vetr downgraded shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) from a sell rating to a strong sell rating in a report published on Tuesday. Vetr currently has $107.00 price target on the biopharmaceutical company’s stock.

ALXN has been the subject of several other research reports. Jefferies Group cut their price target on Alexion Pharmaceuticals from $140.00 to $120.00 and set a hold rating for the company in a report on Friday, September 23rd. Leerink Swann raised their price target on Alexion Pharmaceuticals from $210.00 to $211.00 and gave the company an outperform rating in a report on Monday, September 26th. FBR & Co reaffirmed a sell rating on shares of Alexion Pharmaceuticals in a report on Friday, October 7th. Zacks Investment Research raised Alexion Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, September 27th. Finally, Citigroup Inc. raised their price target on Alexion Pharmaceuticals from $154.00 to $155.00 and gave the company a buy rating in a report on Tuesday, September 20th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have assigned a buy rating to the company. Alexion Pharmaceuticals has a consensus rating of Hold and a consensus target price of $176.10.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 121.34 on Tuesday. Alexion Pharmaceuticals has a 12 month low of $110.56 and a 12 month high of $193.45. The stock has a market cap of $27.21 billion, a PE ratio of 304.87 and a beta of 1.33. The firm has a 50-day moving average of $125.47 and a 200 day moving average of $134.10.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.13 EPS for the quarter, missing the consensus estimate of $1.17 by $0.04. The company earned $753 million during the quarter, compared to analyst estimates of $743.18 million. Alexion Pharmaceuticals had a net margin of 3.19% and a return on equity of 10.02%. The company’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.44 EPS. Analysts anticipate that Alexion Pharmaceuticals will post $4.67 EPS for the current year.

In related news, CEO David Hallal sold 332 shares of the firm’s stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $137.14, for a total value of $45,530.48. Following the sale, the chief executive officer now directly owns 189,266 shares of the company’s stock, valued at $25,955,939.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Alvin S. Parven sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $136.53, for a total value of $2,047,950.00. Following the completion of the sale, the director now directly owns 6,373 shares in the company, valued at $870,105.69. The disclosure for this sale can be found here. 4.41% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in ALXN. MAI Capital Management raised its stake in Alexion Pharmaceuticals by 21.5% in the third quarter. MAI Capital Management now owns 5,201 shares of the biopharmaceutical company’s stock valued at $637,000 after buying an additional 920 shares during the period. National Pension Service raised its stake in Alexion Pharmaceuticals by 8.7% in the third quarter. National Pension Service now owns 154,603 shares of the biopharmaceutical company’s stock valued at $18,945,000 after buying an additional 12,438 shares during the period. Parametrica Management Ltd acquired a new stake in Alexion Pharmaceuticals during the third quarter valued at $232,000. MSI Financial Services Inc raised its stake in Alexion Pharmaceuticals by 1.0% in the third quarter. MSI Financial Services Inc now owns 4,290 shares of the biopharmaceutical company’s stock valued at $526,000 after buying an additional 44 shares during the period. Finally, AT Bancorp acquired a new stake in Alexion Pharmaceuticals during the third quarter valued at $1,102,000. 96.36% of the stock is currently owned by institutional investors and hedge funds.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.